# RUSH UNIVERSITY V MEDICAL CENTER

## Background

- Amyloidosis is a rare disease defined by deposition of extracellular fibrils from immunoglobulin light chains which results in organ dysfunction<sup>1</sup>
- Many patients with primary systemic amyloid have hepatic involvement, but isolated hepatic amyloid deposition is very rare<sup>2,3</sup>
- Hepatic amyloid deposition is characterized by mild hepatomegaly, occasionally elevated liver enzymes, increased echogenicity on ultrasound or decreased attenuation on CT<sup>4,5</sup>
- Biopsy is the gold standard for diagnosis, seen as extracellular amorphous material, and Congo red staining will reveal applegreen birefringence under polarized light
- Leukocyte cell-derived chemotaxin 2 amyloidosis (ALECT-2) is a novel amyloid subtype, previously thought to be found in renal amyloid with a predominance in Hispanic patients but has recently been reported in the liver<sup>6</sup>

# **Patient Presentation**

53-year-old Hispanic female with history of diabetes mellitus, hyperlipidemia, and nonalcoholic fatty liver disease presented to hepatology clinic for elevated liver enzymes.

### **Initial Workup:**

- AST was 36U/L, ALT 67 U/L, ALK P 67 U/L
- Positive ASMA (22U), IgG 1049 mg/dL, normal ANA screen, negative AMA, creatinine 0.71mg/dL
- CT with post-cholecystectomy changes and calcified granuloma but otherwise normal
- Underwent liver biopsy, which demonstrated focal amyloid deposition with positive findings on Congo red stain consistent with amyloidosis as well as mild steatosis, mild lobular activity, and rare ballooning hepatocytes without fibrosis
- Positron emission tomography-CT, bone marrow biopsy, urine and serum protein electrophoresis were unremarkable
- Further amyloid testing showed leukocyte chemotactic factor-2 (ALECT-2) amyloidosis

#### Subsequent Management and Follow-up:

• A referral for second opinion and experimental treatment options was recommended, however the patient declined. The patient has had stable lab values over the last several years with observation

# A Rare Case of Isolated ALECT-2 Hepatic Amyloidosis

Benjamin Schwartz, MD<sup>1</sup>, Jessica Strzepka, MD<sup>1</sup>, Mary Biglin, MD<sup>2</sup>, Ram Al-Sabti<sup>3</sup>, MD, Nikunj Shah, MD<sup>2</sup> <sup>1</sup> Rush University Medical Center, Chicago, IL Department of Internal Medicine; <sup>2</sup> Division of Gastroenterology and Hepatology; <sup>3</sup> Department of Pathology

# Images and Histology





Figure 1: Hematoxylin and eosin stain at high magnification demonstrating hepatic amyloidosis. The pink, amorphous, acellular material seen is amyloid



**Figure 2**: Hepatic sample with Congo Red staining. The salmonpink material is amyloid in a globular configuration, which is typical for ALECT-2

# Lab Values and Disease Course

#### Time

Total protein (g/dL) Albumin (g/dL) Total bilirubin (mg/dL Alkaline phosphatase (IU/L)AST (IU/L) ALT (IU/L)

- enzymes
- treatment regimens
- treatments

- https://journals.lww.com/md-
- doi:10.4254/wjh.v8.i6.340
- doi:10.1016/0002-9343(88)90505-0
- doi:10.1309/AJCPCLK54RKXTRDI

	Initial	Year 1	Year 2	Year 3
	7.3	7.2	7.7	7.1
	4.6	4.4	4.6	4.4
_)	2.7	2.7	3.2	2.4
е	67	66	61	63
	36	57	34	20
	67	96	54	33

## Discussion

• This is a rare case of isolated hepatic amyloidosis, highlighting the need for maintaining a broad differential diagnosis in a patient presenting with elevated liver

Given the rare nature of this condition, it is important to highlight this patient's presentation and three-year outcomes with observation given lack of available

ALECT-2 may have a more indolent clinical course compared to other amyloidosis types<sup>8</sup>, and differentiating it from other causes of amyloidosis avoids other harmful

### References

1. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) Hepatic Amyloidosis: Clinical Features and Natural History in 98 Patients. *Medicine*. 2003;82(5).

journal/Fulltext/2003/09000/Primary AL Hepatic Amyloidosis Clinical.1.aspx

2. Sonthalia N, Jain S, Pawar S, Zanwar V, Surude R, Rathi PM. Primary hepatic amyloidosis: A case report and review of literature. World J Hepatol. 2016;8(6):340-344.

3. Gertz MA, Kyle RA. Hepatic amyloidosis (Primary [AL], immunoglobulin light chain): The natural history in 80 patients. *The American Journal of Medicine*. 1988;85(1):73-80.

4. Kim SH, Han JK, Lee KH, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol. 2003;58(8):610-620. doi:10.1016/s0009-9260(03)00142-9

Damlaj M, Amre R, Wong P, How J. Hepatic ALECT-2 Amyloidosis Causing Portal Hypertension and Recurrent Variceal Bleeding: A Case Report and Review of the Literature. American Journal of Clinical Pathology. 2014;141(2):288-291.

6. Mann BK, Bhandohal JS, Cobos E, Chitturi C, Eppanapally S. LECT-2 amyloidosis: what do we know? J Investig Med. 2022;70(2):348. doi:10.1136/jim-2021-002149